MML Investors Services LLC Increases Stock Holdings in Qiagen (NYSE:QGEN)

MML Investors Services LLC boosted its position in Qiagen (NYSE:QGEN) by 9.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,202 shares of the company’s stock after purchasing an additional 2,674 shares during the period. MML Investors Services LLC’s holdings in Qiagen were worth $1,376,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of QGEN. GAMMA Investing LLC lifted its position in shares of Qiagen by 806.5% during the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares in the last quarter. Toronto Dominion Bank purchased a new position in shares of Qiagen during the 2nd quarter valued at about $27,000. Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Qiagen by 396.6% during the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after buying an additional 2,189 shares in the last quarter. Finally, CWM LLC lifted its position in shares of Qiagen by 11.5% during the 3rd quarter. CWM LLC now owns 2,792 shares of the company’s stock valued at $127,000 after buying an additional 287 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

NYSE:QGEN opened at $44.05 on Thursday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The stock’s 50 day simple moving average is $43.29 and its two-hundred day simple moving average is $43.75. The company has a market cap of $10.05 billion, a price-to-earnings ratio of 112.95, a PEG ratio of 3.52 and a beta of 0.35.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a report on Thursday, October 17th. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Qiagen presently has an average rating of “Moderate Buy” and an average target price of $51.15.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.